I'm LongbridgeAI, I can summarize articles.(Yicai) Oct. 27 -- Chinese drugmakers expect their overseas licensing boom to continue despite proposed US biotechnology investment restrictions that could reshape some cross-border deals, industry insiders said.
Traditional license-out deals, a key source of funding for Chinese drugmakers, are expected to remain largely unaffected. But transactions involving American equity investment or newly established overseas companies, known as NewCos, that develop and commercialize licensed drugs face greater uncertainty, industry insiders said.
The US Treasury Department recently released draft implementing rules for the Comprehensive Outbound Investment National Security Act (COINS), proposing to bring biotechnology under outbound investment restrictions. The public comment period runs through Dec. 7.
Overseas licensing has become a key way for Chinese drugmakers to fund drug development and expand globally, with deals worth USD130 billion signed in the first nine months of this year, nearly matching the total for 2025.
At the 11th China BioMed Innovation and Investment Conference, a representative of a multinational pharmaceutical company said the firm has engaged lawyers to interpret the proposed rules. Traditional license-out transactions remain generally open, but the potential impact on equity investments and NewCo-related businesses remains unclear, the person noted.
Investors are also weighing the potential impact. Pivotal BioVenture Partners, an American venture capital firm that focuses on life sciences, said that it is still assessing the proposed rules and has yet to reach a conclusion, according to Dan Liu, the firm's managing partner in China.
Industry Seeks Ways Forward
For Chinese drugmakers, navigating the proposed restrictions will require closer scrutiny of cross-border transactions, even as executives remain confident about future cooperation.
Chinese drugmakers need to conduct legal, financial, compliance, and intellectual property reviews early in cross-border licensing deals and strengthen risk controls when drafting contract terms, said Gloria Luo, senior director of business development at Hengrui Pharmaceuticals, a Chinese firm focused on oncology, immunology, and metabolic diseases.
Trency Gu, managing director at HongShan, formerly known as Sequoia Capital China, said companies can find workable solutions as long as regulators provide clear and detailed rules, adding that solutions tend to outnumber difficulties.
He Xiang, chief financial officer of Chinese drugmaker 3SBio, also expressed confidence in the outlook for overseas licensing. European pharmaceutical companies face relatively less pressure from the proposed US restrictions, and while government policies reflect broader strategic interests, private-sector pharmaceutical cooperation will continue as companies find ways to operate within existing regulatory frameworks, He said.
Overseas drugmakers still need to replenish their research and development pipelines and offset revenue losses from expiring patents, said Luo Fei, founding partner of VC firm Green Pine Capital Partners. Chinese pharmaceutical companies have spent the past decade building competitive capabilities in early-stage drug discovery, clinical development, and drug delivery technologies, he added.
However, Chinese innovative drugmakers still need to strengthen their global development and commercialization capabilities to move beyond licensing drug candidates and capture more value from bringing medicines to international markets, industry insiders noted.
Editor: Emmi Laine
